Recombinant factor IX: Discrepancies between one-stage clotting and chromogenic assays

Haemophilia

Volumn 20, Issue 6, 2014, Pages 891-897

  Wilmot, Helen V ^a   Hogwood, J ^a   Gray, E ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Chromogenic assay; Factor concentrates; Onestage clotting assay; Plasma derived factor IX; Recombinant factor IX; Standardization

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9; RECOMBINANT PROTEIN;

ARTICLE; BLOOD EXAMINATION; CHROMOGENIC ASSAY; CONTROLLED STUDY; DRUG DETERMINATION; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL STANDARD UNIT; ONE-STAGE CLOTTING ASSAY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STANDARDIZATION; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; HEMOPHILIA B; PROCEDURES; STANDARDS;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR IX; HEMOPHILIA B; HUMANS; RECOMBINANT PROTEINS;

EID: 84923326141     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12449     Document Type: Article

References (27)

1. Brozović M, Kirkwood TB, Robertson I. Study of a proposed international standard for coagulation factor IX. Thromb Haemost 1976; 35: 222-36.
2. Hubbard AR, Weller LJ, Bevan SA. A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates. Br J Haem 2002; 117: 247-54.
3. Mikaelsson M, Oswalksson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Haem 2001; 38: 13-23.
4. Barrowcliffe TW, Hubbard AR, Kitchen S. Standards and monitoring treatment. Haemophilia 2012; 18: 61-5.
5. Gray E, Pickering W, Hockley J et al. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards. Pharmeuropa Bio 2008; 2008: 19-30.
6. Holm PK, Sorensen MH, Hermit MB, Ezban M. The activity of GlycoPEGylated recombinant FIX (N9-GP) can be measured in two-stage chromogenic and one-stage clotting assays. 2013; PB 3.49-1, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=217022&congressId=6839. Accessed November 13, 2013.
7. Lochu A, Romari N, Beltram J, Magdelaine A, Hermit MB, Ezban M. Influence of FIX and FVIII PEGYLATION on FIX and FVIII activity based on APTT assays. 2013; PB4.54-1, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=217440&congressId=6839. Accessed November 13, 2013.
8. Sommer J, Yang B, Peters R, Jiang H, Gray E, Pierce GF. Comparative field study evaluating the activity of recombinant Factor IX-Fc fusion protein (rFIXFc) in plasma samples at clinical haemostasis laboratories. PB3.49-2, Abstract at XXIV Congress of the International Society on Thrombosis and Haemostasis. Available at http://www.eventure-online.com/eventure/publicAbstractView.do?id=216611&congressId=6839. Accessed November 8, 2013.
9. Assay of human coagulation factor IX. Eur Pharm 2012; monograph 01/2008:20711.
10. Statistical analysis of results of biological assays and tests. Eur Pharm 2012; monograph 01/2008:50300.
11. FDA. Summary basis for regulatory action. Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm363090.pdf. Accessed November 13, 2013.
12. Baxter. RIXUBIS product insert. Available at: http://www.baxter.com/downloads/healthcare_ professionals/products/RIXUBIS_PI.pdf. Accessed November 13, 2013.
13. Barrowcliffe TW. Insights from factor IX activation studies with chromogenic assays: implications of dispartate product results. Haemophilia 2010; 16(Suppl. 6): 9-12.
14. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
15. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
16. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assess-ment of FVIII activity. Haemophilia 1998; 4: 646-50.
17. Caron C, Dautzenberg MD, Delahousse B et al. A blinded in vitro study with Refacto ® mock plasma samples: similar FVIII results between the chromogenic assay and a onestage assay when using a higher cephalin dilution. Haemophilia 2002; 8: 639-43.
18. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in haemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost 2002; 28: 257-64.
19. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4: 641-5.
20. Windyga J, Lissitchov T, Stasyshyn O et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/II study in previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level = 2%) haemophilia B. Haemophilia 2014; 20: 15-24.
21. Martinowitz O, Shapiro A, Quon DV et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialyation analysis. Haemophilia 2012; 18: 881-7.
22. Østergaard H, Bjelke JR, Hansen L et al. Prolonged half life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118: 2333-41.
23. Peters RT, Low SC, Kamphaus GD et al. Prolonged activity of factor IX as a fusion protein. Blood 2010; 115: 2057-64.
24. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S. Genetic fusion to albumin improves the pharmokinetic properties of factor IX. Thromb Haemost 2009; 102: 634-44.
25. Hubbard AR, Dodt J, Lee T et al.; on behalf of the factor VIII and factor IX subcommittee of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Recommendations on the potency labelling of FVIII and factor FIX concentrates. J Thromb Haemost 2013; 11: 988-9.
26. Aronson DL, Thomas DP. The control and standardization of factor VIII. Scand J Haematol Suppl 1984; 41: 71-8.
27. Hubbard AR. International biological standards for clotting factors and inhibitors. Semin Thromb Hemost 2007; 33: 283-9.